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Neutrophil infiltration is a hallmark of peritoneal inflammation, but mechanisms 
regulating neutrophil recruitment in patients with peritoneal dialysis (PD)-related 
peritonitis are not fully defined. We examined 104 samples of PD effluent collected during 
acute peritonitis for correspondence between a broad range of soluble parameters and 
neutrophil counts. We observed an association between peritoneal IL-17 and neutrophil 
levels. This relationship was evident in effluent samples with low but not high IFN-γ levels, 
suggesting a differential effect of IFN-γ concentration on neutrophil infiltration. 
Surprisingly, there was no association of neutrophil numbers with the level of CXCL1, a 
key IL-17-induced neutrophil chemoattractant. We investigated therefore the production 
of CXCL1 by human peritoneal mesothelial cells (HPMCs) under in vitro conditions 
mimicking clinical peritonitis. Stimulation of HPMCs with IL-17 increased CXCL1 
production through induction of transcription factor SP1 and activation of the SP1-binding 
region of the CXCL1 promoter. These effects were amplified by TNFα. In contrast, IFN-γ 
dose-dependently suppressed IL-17-induced SP1 activation and CXCL1 production through 
a transcriptional mechanism involving STAT1. The SP1-mediated induction of CXCL1 was 
also observed in HPMCs exposed to PD effluent collected during peritonitis and containing 
IL-17 and TNFα, but not IFN-γ. Supplementation of the effluent with IFN-γ led to a dose-
dependent activation of STAT1 and a resultant inhibition of SP1-induced CXCL1 expression. 
Transmesothelial migration of neutrophils in vitro increased upon stimulation of HPMCs 
with IL-17 and was reduced by IFN-γ. In addition, HPMCs were capable of binding CXCL1 
at their apical cell surface. These observations indicate that changes in relative peritoneal 
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concentrations of IL-17 and IFN-γ can differently engage SP1-STAT1, impacting on 
mesothelial cell transcription of CXCL1, whose release and binding to HPMC surface may 
determine optimal neutrophil recruitment and retention during peritonitis. 
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Peritonitis continues to represent a common complication of peritoneal dialysis 
(PD) [1], which can lead to treatment failure. An early phase of peritonitis involves a 
massive neutrophil infiltration that is driven by local secretion of neutrophil-specific 
chemoattractants. These include chemokines, such as CXC-chemokine ligand 1 (CXCL1), 
derived from the peritoneal mesothelium. Human peritoneal mesothelial cells (HPMCs) 
respond rapidly to classic pro-inflammatory cytokines IL-1β and TNFα by secreting huge 
quantities of CXCL1 [2]. More recently, IL-17 has been identified as another inducer of 
neutrophil-mediated responses [3]. We have previously demonstrated that IL-17 strongly 
stimulates HPMCs to produce CXCL1 in vitro and promotes CXCL1-mediated neutrophil 
trafficking in mice [4]. However, the mechanisms by which IL-17 controls the magnitude of 
chemokine production and neutrophil infiltration during peritonitis in humans are not 
fully defined. 
IL-17 originates largely from TH17 and γδ T cells, but other cell types may also 
contribute [5,6]. Whilst IL-17 is virtually undetectable in a healthy human peritoneum, it 
appears in peritoneal biopsies from patients undergoing PD [7]. The expression of IL-17 
correlates with the duration of PD treatment and the extent of peritoneal inflammation and 
fibrosis. The concentration of IL-17 in the dialysis effluent increases variably at the onset 
of peritonitis [8] and declines when the infection resolves [9]. Interestingly, IL-17 levels 
seem to be higher in patients with rapid response to antibiotic treatment compared with 
those with a delayed response [9]. This may indicate that local IL-17 contributes to the 
peritoneal host defence. In this respect, IL-17 seems to be crucially involved in the 
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immunity against staphylococci [10]. Peritoneal inoculation of S. aureus in mice leads to 
rapid recruitment of IL-17-producing cells and expansion of memory γδ T cells, which 
produce high levels of IL-17 promptly after re-infection with S. aureus [11]. The IL-17 
responses to staphylococci may be initiated by the activation of Toll-like receptor 2 (TLR2) 
resulting in the production of cytokines which stimulate IL-17-expressing cells [10]. 
On the other hand, excessive accumulation of IL-17 precedes formation of 
adhesions and abscesses after peritoneal infection or surgical injury in mice [12,13]. These 
complications can be prevented by blocking either IL-17 or the receptor CXCR2 for 
neutrophil-specific chemokines, including CXCL1 [13]. In the context of PD, daily injections 
of PD fluids in mice lead to the infiltration of the peritoneum by TH17 and γδ T cells and 
increased peritoneal IL-17 [7,14]. 
The magnitude of IL-17-induced CXCL1 expression is regulated by transcriptional 
and post-transcriptional mechanisms [15]. The post-transcriptional control is related 
predominantly to stabilization of CXCL1 mRNA [16,17]. The mechanism of transcriptional 
CXCL1 activation is less clear [15,18]. This occurs partly through activation of the 
transcription factor NF-κB [19,20]. However, the involvement of other transcription factors 
is also possible [15]. 
IFN-γ is a key mediator of TH1 cell responses, but it is also derived from γδ T cells 
[21]. Moreover, TH17 cells show developmental plasticity that allows them to express IFN-γ 
in addition to IL-17 [22]. In the peritoneum IFN-γ acts jointly with IL-6 and contributes 
both to the recruitment and clearance of neutrophils [23]. Early during peritonitis IFN-γ 
ensures the generation of CXC chemokines at the level necessary for effective neutrophil 
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recruitment. At later stages IFN-γ controls neutrophil removal by down-regulating CXC 
chemokine production [24,25].  
The functions of IFN-γ are mediated by direct activation of target genes but also by 
cross-regulation of responses to other cytokines [26]. It is increasingly clear that the 
interaction between IFN-γ and IL-17 is important for the effective host response to 
infection. While the suppressive effect of IFN-γ on TH17 cell differentiation is well 
recognized [27], little is known about the effect of IFN-γ on effector functions of IL-17. 
Considering that the interplay between IFN-γ and IL-17 depends strictly on the 
pathophysiological context and is less understood in humans than in mice, we set out to 
investigate whether IL-17 and IFN-γ interact to modulate neutrophil influx during PD and 
exert transcriptional control over expression of CXCL1 in human mesothelium. 
  





Unless stated otherwise, all chemicals were from Sigma-Aldrich (St Louis, MO, USA) 
and culture plastics were Falcon® from Corning Life Sciences (Tewksbury, MA, USA). 
Human recombinant IL-17, IFN-γ, TNFα, and CXCL1 were from R&D Systems (Bio-Techne; 
Wiesbaden, Germany). The specific activity of IFN-γ was 2 x 104 WHO standard units per 1 
μg protein (1 U/ml = 50 pg/ml).  
Patient samples 
Samples of PD effluent (104 samples; 68 male and 36 female samples) were 
obtained from separate infective episodes from 87 patients (30 female patients, 57 male 
patients). The samples were collected in the course of the “Patient Immune Responses to 
Infection in PD” (PERIT-PD) study, registered on the UK Clinical Research Network 
Portfolio (no. 11838). The study was approved by the South East Wales Local Ethics 
Committee (04WSE04/27) and all patients provided written informed consent. Subjects 
positive for HIV or hepatitis C were excluded from the study. All samples were from the 
first day of presenting at hospital with a cloudy bag, before commencing antibiotic 
treatment. The patient characteristics are summarized in supplementary material, Table 
S1. 
An exemplar peritoneal effluent used in the in vitro experiments was from a patient 
with Enterobacter cloacae peritonitis. Cytokine concentrations in the effluent were 
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determined using Quantikine ELISA kits (R&D Systems, Bio-Techne; Wiesbaden, Germany), 
and the recorded levels were: IL-17, 4 pg/ml; IFN-γ, undetectable; TNFα, 231 pg/ml.  
Cells from peritoneal effluents were analysed as previously described [28] and 
detailed in supplementary material, Supplementary material and methods.  
Mesothelial cell culture 
HPMCs were cultured as previously described [29]. For the experiments, cells were 
rendered quiescent by serum deprivation for 24 h and then stimulated as specified in 
figure legends. All experiments were performed with cells from the third passage and not 
later to minimize the number of senescent cells, as this may affect the level of CXCL1 
released [30]. 
Immunoassays  
CXCL1 concentration in cell culture supernatants was measured using DuoSet 
Immunoassay Kit (R&D Systems, Bio-Techne; Wiesbaden, Germany). Binding of 
recombinant CXCL1 to HPMCs was assessed by an immunoassay according to van Gemst et 
al [31]. CXCL1 and other soluble parameters in cell-free peritoneal effluents were 
measured as described [28]. Details of these immunoassays and CXCL1 binding 
experiments are provided in supplementary material, Supplementary material and 
methods.  
Gene expression analysis 
Expression of target genes relative to β2-microglobulin (B2M) mRNA was assessed 
using reverse transcription and quantitative PCR (RT-qPCR), as described [29]. The data 
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are presented as a fold-change over control levels in untreated cells. PCR conditions are 
specified in supplementary material, Supplementary materials and methods. PCR primer 
sequences are listed in supplementary material, Table S2. 
DNA Constructs and Reporter Plasmids 
Genomic DNA from HPMCs was isolated with Isol-RNA Lysis Reagent (5 Prime, 
Hamburg, Germany) and used to generate progressive CXCL1 luciferase plasmid constructs 
(pLuc 1700, pLuc 1120, pLuc 620 and pLuc 150) through PCR amplification with 
appropriate primer pairs. The Infusion Cloning Kit (Takara Bio, Mountain View, CA, USA) 
was used with the pGL4.10 vector backbone to create the luciferase reporter constructs. 
The length of the promoter segments was verified by restriction digestion and sequencing 
(LGC Genomics, Berlin, Germany). To target specific binding sites within the CXCL1 
promoter, the desired sequence was inserted into the CXCL1 construct using the Q5 Site–
Directed Mutagenesis Kit (New England BioLabs, Frankfurt, Germany), as detailed in 
supplementary material, Supplementary materials and methods. 
Transfection studies 
Transient transfection and luciferase assays were performed as previously 
described [29] using the siRNA Transfection Reagent (Santa Cruz Biotechnology, 
Heidelberg, Germany). The siRNAs used are listed in supplementary material, 
Supplementary materials and methods.  
Computational analysis of the CXCL1 promoter 
The human CXCL1 promoter region −519 to −51 (GenBank NC_000004.12) was 
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analysed using PROMO virtual laboratory (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) for the presence and location of 
potential transcription factor binding sites. 
Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation 
(ChIP) 
Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic 
Extraction Kit (Thermo Scientific, Darmstadt, Germany). Formaldehyde cross-linking and 
ChIP was performed using a ChIP-IT High Sensitivity Kit (Active Motif, Carlsbad, CA, USA). 
The conditions of EMSA and ChIP are summarized in supplementary material, 
Supplementary material and methods  
Western blotting 
Cell extracts were prepared as described [32], electrophoresed on sodium dodecyl 
sulphate-polyacrylamide gels and immune-blotted using antibodies listed in the 
supplementary material, Table S3. The bands obtained were visualized and analysed using 
an Enhanced Chemiluminescence Detection System (Thermo Scientific, Darmstadt, 
Germany) and ImageJ 1.43 software (National Institutes of Health, Bethesda, MD, USA). 
Neutrophil transmigration assay 
Neutrophil migration was measured using aTranswell assay, as previously described 
[33]. Migration was assessed in response to conditioned medium from HPMCs or through 
HPMC monolayers established on Transwells [34] as specified in the supplementary 
material, Supplementary materials and methods.  





All patients’ data was processed in R software (version 3.5.0), using base packages 
and VGAM, tidyverse and stringr. Data with missing values were excluded from the study. 
To compute the threshold for the effect of IFN-γ expression on IL-17 activity in vivo, R2 
values of IL17 versus neutrophil numbers were calculated for all possible IFN-γ 
thresholds. A Loess curve was fitted to the relationship between R2 and IFN-γ, and local 
maxima were found for the data below and above the threshold. By repeating the analysis 
with random sets of 100 samples, a clear maximum in combined R2 was seen when the 
threshold was between 23.8–25.4 pg/ml IFN-γ. This was averaged to 24.5 pg/ml for use in 
further analyses. 
All other analyses were performed using GraphPad Prism 8.0 software (GraphPad 
Software, San Diego, CA, USA). The data were analysed with the t-test or repeated 
measures analysis of variance for paired data. Results were expressed as mean ± SD. 
Differences with a P value <0.05 were considered significant.  




Association between neutrophil influx during peritonitis and intraperitoneal IL-17 
and IFN-γ levels 
First, we examined whether there existed a correspondence between peritoneal 
levels of IL-17 and/or IFN-γ and neutrophil numbers. These were measured in 104 
samples of dialysate effluent from patients with acute peritonitis. As expected, neutrophils 
were increased in the culture-positive samples, but no distinction could be made between 
neutrophil numbers in Gram-positive and Gram-negative bacterially infected patients 
(Figure 1A). Similarly, IL-17 was lower in culture-negative compared to culture-positive 
samples (Figure 1B). The distributions of IL-17 levels were very broad in both Gram-
positive and -negative infections, and were not distinguishable between the two. In 
contrast, the distributions of IFN-γ levels were largely the same in patients with culture-
negative and culture-positive peritonitis with only a longer high-expressing tail in Gram-
positive infections (Figure 1C). When IL-17 and neutrophil numbers were plotted, IL-17 
showed a moderate but highly significant association with neutrophil levels (Figure 1E). 
IFN-γ showed a weak association that could be fitted with a quadratic equation (Figure 
1F), suggesting a differential effect of low and high IFN-γ concentrations. Modelling 
neutrophil numbers with respect to interactions between IFN-γ and IL-17 showed that 
including interaction terms with IFN-γ improved the fit. Indeed, if samples were separated 
into groups expressing low (<24.5 pg/ml) or high (≥24.5 pg/ml) IFN-γ levels, it could be 
seen that IL-17 had a significant association with neutrophil numbers in samples with low 
IFN-γ but no association with neutrophil numbers in the presence of higher IFN-γ 
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concentrations (Figure 1G). This analysis suggested that low IFN-γ levels allowed for the 
expression of the IL-17 phenotype with respect to increasing neutrophil influx. 
Interestingly, the pattern of expression of IL-17 and its effect on neutrophil numbers was 
paralleled by those of IL-12p40 (a member of the IL-17/IL-23 axis) and IL-16 
(supplementary material, Figure S1A,B). This was in contrast to mediators derived 
primarily from neutrophils (matrix metalloproteinase (MMP)-8, neutrophil gelatinase-
associated lipocalin (NGAL), myeloperoxidase), which were tonically up-regulated 
independently of IFN-γ levels (supplementary material, Figure S1C–E), and also to a wide 
range of chemokines and cytokines unrelated to the IL-17 pathway (such as IL-2, IL-
12p70, and TNFα), which showed no correspondence to neutrophil levels (supplementary 
material, Figure S1F–H). Surprisingly, there was also no appreciable association of 
neutrophil numbers with a key neutrophil-attracting chemokine CXCL1 (Figure 1D and H).  
Effect of IL-17 and IFN-γ on CXCL1 secretion and expression by HPMCs 
To understand the observed paradox, we analysed the interaction between IL-17 
and IFN-γ with respect to CXCL1 production by HPMCs in vitro. Exposure of HPMCs to IL-
17 resulted in a time- and dose-dependent increase in CXCL1 secretion. This increase was 
significantly reduced by IFN-γ (Figure 2A,B). Half-maximal inhibitory concentration of IFN-
γ (IC50) for this effect was 280±95 pg/ml. Anti-IFN-γ antibodies, but not control IgG, 
abolished the inhibitory activity of IFN-γ confirming the specificity of its effect towards 
CXCL1 (Figure 2C). A similar inhibition of IL-17 activity by IFN-γ was also observed at the 
mRNA level (Figure 2D).  
This article is protected by copyright. All rights reserved.
 
 
Effect of IL-17 and IFN-γ on activation of the CXCL1 gene promoter 
Exposure of HPMCs transiently transfected with CXCL1 luciferase reporter gene 
constructs to IL-17 strongly increased activity of the full-length CXCL1 promoter 
(Figure 2E). IFN-γ alone exerted no effect on promoter activity, but it reduced the activity 
induced by IL-17. Truncation of successive CXCL1 promoter fragments revealed that IL-17 
activity was mediated within a promoter region spanning positions -519 to -51 
(Figure 2F). In silico analysis determined that this region contained high affinity binding 
sites for the transcription factors Stimulating Protein-1 (SP1) and Signal Transducer and 
Activator of Transcription-1 (STAT1). The STAT1-binding site mutation did not affect the 
activation of the CXCL1 promoter by IL-17, but prevented IFN-γ from inhibiting IL-17-
induced activity (Figure 2G). On the other hand, the level of SP1 mRNA increased 
significantly in response to IL-17 and decreased after the addition of IFN-γ (Figure 2H).  
Effect of IL-17 and IFN-γ on activation of the transcription factor SP1  
Nuclear extracts from IL-17-treated HPMCs formed a DNA-protein complex with a 
consensus oligonucleotide for SP1 binding that encompassed positions -227 to -250 of the 
CXCL1 promoter (Figure 3A). The specificity of SP1 binding was confirmed by EMSA with 
anti-SP1 antibody, which dose-dependently supershifted the DNA-protein complex (Figure 
3B). Another EMSA showed that IFN-γ alone had no effect on SP1 binding, however, it 
completely abolished the effect of IL-17 (Figure 3C). ChIP using the PCR-amplified 
fragment of the CXCL1 promoter and HPMC-derived chromatin precipitated with an SP1 
antibody confirmed that IL-17 stimulated SP1 binding to the CXCL1 promoter (Figure 3D) 
and that this effect was eliminated by IFN-γ (Figure 3E).  
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The functional role of SP1 for CXCL1 induction was also confirmed by stimulating 
HPMCs with IL-17 in the presence of SP1-targeting siRNA, which led to inhibition of CXCL1 
mRNA (Figure 3F).  
Role of IFN-γ-STAT1 signalling in modulation of IL-17-induced CXCL1 expression  
Whilst the above experiments demonstrated the role of SP1 in the induction of CXCL1 by 
IL-17, these did not fully elucidate the mechanism of modulatory activity of IFN-γ. 
Experiments using site-directed mutagenesis (see above) suggested that this effect 
occurred through STAT1. Indeed, the addition of IFN-γ to IL-17-stimulated HPMCs resulted 
in a significant up-regulation of STAT1 protein by a mechanism that was blocked by STAT1-
specific RNA interference (Figure 4A). When HPMCs stimulated with IL-17+IFNγ were 
treated with STAT1-siRNA, the ability of IFN-γ to down-regulate SP1 and CXCL1 expression 
was lost (Figure 4B,C). ChIP analysis confirmed that exposure to IFN-γ led to association of 
STAT1 with the CXCL1 promoter DNA (Figure 4D).  
Effect of TNFα on IL-17-induced SP1-mediated CXCL1 expression  
We previously demonstrated that TNFα amplified IL-17-induced CXCL1 release [4]. 
Here, we analysed whether this effect involved SP1. The addition of TNFα to IL-17-treated 
HPMCs led to a significant increase in both SP1 and CXCL1 mRNAs, but only a marginal 
induction of STAT1. Administration of IFN-γ to IL-17+TNFα-treated HPMCs resulted in a 
significant up-regulation of STAT1 and a dose-dependent decrease in SP1 and CXCL1 
expression (supplementary material, Figure S2A–C).  
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Role of SP1- and STAT1-mediated pathways in dialysate-induced CXCL1 expression 
during peritonitis 
To mimic the conditions of clinical PD, HPMCs were exposed to the effluent obtained 
from a model PD patient presenting with peritonitis. We asked whether such an effluent 
could induce CXCL1 in HPMCs through the newly identified mechanisms. To this end, the 
effluent containing IL-17 but no IFN-γ was used, as it was hypothesised it would show an 
uninhibited effect towards CXCL1. Indeed, exposure of HPMCs to this effluent resulted in 
an increase in both CXCL1 and SP1 mRNAs (Figure 5A,B), and the increased CXCL1 
expression was reduced with SP1-siRNA (Figure 5C). Although this inhibitory effect 
confirmed the contribution of the SP1 to CXCL1 induction, its magnitude was surprising 
given that the level of IL-17 in this particular effluent was rather low. We hypothesised that 
IL-17 synergized with TNFα whose concentration in the effluent was quite substantial. 
Indeed, the stimulatory effect of the effluent on CXCL1 and SP1 expression was significantly 
reduced by antibodies neutralizing IL-17 and TNFα (Figure 5D,E). As IFN-γ was not 
detected in the effluent, we spiked it with increasing doses of exogenous IFN-γ. The 
addition of IFN-γ resulted in a significant decrease in effluent-induced CXCL1 and SP1 
expression (Figure 5F,G). This effect was associated with a marked dose-dependent 
induction of STAT1 by IFN-γ (Figure 5H).  
Effect of HPMC exposure to IL-17 and IFN-γ on neutrophil migration 
To see whether HPMCs exposed to IL-17±IFN-γ modulate migration of neutrophils, 
we first assessed the effect of medium conditioned by HPMCs. The samples from IL-17-
treated HPMCs produced a strong migratory response in neutrophils in a Transwell assay 
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(Figure 6A). Surprisingly, the effect of medium from HPMCs treated with IL-17±IFN-γ was 
not different from that of IL-17 alone. We then assessed neutrophil transmigration through 
HPMC monolayers seeded on Transwells and stimulated with IL-17±IFN-γ. Also, in this 
setting IL-17 induced neutrophil migration, however, the addition of IFN-γ significantly 
reduced the effect (Figure 6B). This suggested that the presence of HPMCs played a key 
role in controlling leukocyte migration. Since it has recently been demonstrated that 
neutrophil migration during peritonitis in mice depends on the expression of CXCL1 over 
the mesothelial surface [35], we tested whether CXCL1 could bind to HPMCs. After the 
exposure of HPMCs to recombinant CXCL1, the presence of CXCL1 was detected on HPMC 
surface by immunoassay (Figure 6C).  
  




Having observed that the number of neutrophils infiltrating the peritoneum during 
peritonitis associated with IL-17, we analysed the mechanism by which IL-17 induced a 
neutrophil-attracting chemokine CXCL1 in HPMCs. We identified the transcription factor 
SP1 being pivotal to this process, which is a novel finding, since SP1 has not previously 
been linked with IL-17-induced genes. Many IL-17 target genes are thought to be activated 
through NF-kB, as their promoters are often enriched in NF-κB binding sites [18]. While IL-
17 can activate NF-κB in HPMCs [36], our study demonstrates that the effect of IL-17 on 
CXCL1 transcription is ultimately mediated by SP1.  
Although SP1 is ubiquitously expressed, its transcriptional activity differs 
considerably across the tissues [37]. Except for the finding that SP1 is required for CXCL1 
transcription in retinal and melanoma cells [38], there were no other reports showing the 
involvement of SP1 in IL-17-induced responses and the CXCL1 promoter regulation. Thus, 
it remains to be determined whether our observation represents a general phenomenon or 
it is an example of tissue specific-regulation. 
The SP1-mediated activity of IL-17 could be dampened by IFN-γ through a 
mechanism involving STAT1. This is an interesting finding since the interactions between 
STAT1 and SP1 are poorly recognized. There were only few reports on the SP1-STAT1 co-
operation, which turned out to be necessary for full transcriptional gene activation 
[39,40,41,42,43]. That STAT1 can curtail rather than amplify SP1-driven CXCL1 
transcription reveals a novel aspect of transcriptional control. STAT1-deficiency in mice 
was found to increase CXCL1 expression and neutrophil infiltration, which could be 
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suppressed by blocking IL-17 [44]. In humans, the gain-of-function STAT1 mutations 
inhibited the development of IL-17-producing T cells and impaired IL-17 immunity [45]. 
Introduction of the human STAT1 mutation into mice decreased the number of IL-17-
producing cells upon C. albicans infection [46]. Moreover, the death receptor Fas was 
demonstrated to promote TH17 cell development by preventing STAT1 activation [47]. 
Indeed, some FAS polymorphisms affected the interactions between SP1 and STAT1 and 
their recruitment to the FAS promoter [43]. 
IL-17 is particularly important for mucocutaneous host defence [15,48]. Our 
observations suggest that IL-17 may play a similar role in the serosal membranes. By 
inducing the CXCL1 production in HPMCs and amplifying the effects of TNFα during 
peritonitis, IL-17 may facilitate prompt neutrophil recruitment and effective bacterial 
clearance. In turn, IFN-γ may act as a safeguard mechanism protecting against excessive 
neutrophil infiltration. Consequently, the relative concentrations of IL-17 and IFN-γ may 
underlie the course of infection. In this respect, it has been determined that different 
bacteria induce distinct ‘immune fingerprints” of soluble mediators in the peritoneal 
effluent [28] and may thus create a specific microenvironment promoting differentiation 
of either IL-17- or IFN-γ producing cells. Involvement of IL-17 in the regulation of 
neutrophil influx during peritonitis is supported by the fact that the same pattern of 
interaction with IFN-γ was observed for other cytokines of the IL-17 axis but not for 
members of other signalling pathways.  
It will be interesting to examine whether the interplay between SP1 and STAT seen 
in HPMCs occurs in conditions other than PD. It has been reported that impaired IFN-γ 
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signalling exacerbated IL-17-mediated neutrophil infiltration of joints in murine arthritis 
[49], and that IFN-γ prevented excessive IL-17-mediated neutrophil accumulation in 
tuberculosis [50]. In addition, IFN-γ priming of macrophages was found to decrease, 
possibly through a STAT1-dependent mechanism, expression of several IL-17-inducible 
genes, including CXCL1 [51].  
Immune responses to environmental threats are driven by subpopulations of TH 
cells and aim to restore an equilibrium, which protects tissues from damaging 
inflammation [52]. In contrast, an unbalanced response may lead to inflammatory 
pathologies. According to this paradigm, our demonstration of IFN-γ down-regulating IL-
17-induced CXCL1 production can be viewed as a mechanism controlling neutrophil 
recruitment and ensuring resolution of inflammation. On the other hand, excessive STAT1-
mediated IFN-γ signalling may impair the host’s ability to mount an IL-17-driven response 
to effectively clear infection. In the context of PD, it has been demonstrated that repeat 
episodes of acute peritonitis lead to expansion of TH1 cells, which outnumber IL-17-
producing cells [53]. Importantly, the exaggerated STAT1 signalling that is associated with 
such repeat peritoneal inflammation has been demonstrated to underlie the development 
of peritoneal fibrosis [54]. 
Interestingly, the suppressive effect of IFN-γ on IL-17-induced CXCL1 expression in 
HPMCs in vitro did not translate into the corresponding pattern of neutrophil migration in 
response to conditioned medium from HPMCs stimulated with IL-17±IFN-γ. However, it 
became apparent when neutrophils migrated across the monolayer of stimulated HPMCs. 
This suggested that not only the released chemokines but also the presence of HPMCs 
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contributed to leukocyte trafficking. In this regard, it has recently been demonstrated that 
intraperitoneal neutrophil migration during peritonitis occurs predominantly in the 
omental immune cell clusters (known as milky spots), which are covered by specialised 
mesothelial cells secreting and retaining CXCL1 [35]. This enables neutrophils to form 
dense aggregates on the mesothelial surface and trap invading microorganisms. Since our 
HPMC isolates were of omental origin, it was possible that they could retain on their 
surfaces some of the CXCL1 produced. Indeed, we showed that HPMCs were capable of 
binding CXCL1, possibly through cell surface glycosaminoglycans, whose nature remains to 
be established [31]. Such a scenario would explain the absence of straightforward 
association between neutrophil counts and CXCL1 concentration in the dialysate. In fact, 
blocking CXCL1 was found to reduce the number of neutrophils entering the omentum but 
did not affect those in the peritoneal fluid in a zymosan model of peritonitis [35]. 
In conclusion, IL-17 and IFN-γ cross-react through a novel mechanism involving SP-
1 and STAT1 to tailor CXCL1 production by the peritoneal mesothelium (Figure 6D). This 
mechanism may be of clinical relevance as dysregulated CXCL1 release may lead to either 
excessive or ineffective neutrophil recruitment during peritonitis.  
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Figure 1. Associations between neutrophil numbers during peritonitis and 
intraperitoneal levels of IL-17, IFN-γ and CXCL1. (A–C) Distributions of neutrophils, and 
IL-17 and IFN-γ expression in peritoneal effluent from patients with peritonitis. (A) 
Neutrophil count in total peritoneal fluid from patients. (B–D) Concentrations of IL-17 (B), 
IFN-γ (C) and CXCL (D) in peritoneal fluid. Neutrophils were defined and counted using 
flow cytometry on the basis of forward and side scatter and expression of CD15. The 
graphs are density plots, with the y axis representing the likelihood of a sample having a 
particular x value, for data averaged using weights across a small interval to produce a 
smoothed curve. (E–F) Association of IL-17 and IFN-γ levels with neutrophil numbers. (E) 
IL-17 or (F) IFN-γ concentrations were compared to overall neutrophil counts in 
peritonitis samples and either linear or quadratic regressions fitted to the log data. (G) 
Effect of IFN-γ concentrations on the relationship between IL-17 as neutrophil numbers. 
Regression of samples in which IFN-γ was below 24.5 pg/ml (filled circles) as compared to 
those above 24.5 pg/ml (open circles) showed that a relationship between IL-17 
concentration and neutrophil numbers existed below but not above the threshold. (H) 
Comparison of CXCL1 concentrations and neutrophil numbers. The samples were analysed 
using the IFN-γ threshold as above.  
Figure 2. Effect of IL-17 and IFN-γ on CXCL1 secretion and activation of the CXCL1 
gene promoter expression by in HPMCs. (A) Kinetics of CXCL1 secretion in response to 
IL-17 (50 ng/ml), IFN-γ (1.25 ng/ml) or combination thereof. *P<0.05 for comparison IL-
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17 vs. IL-17±IFN-γ at each time point (n=5). (B) Dose effect of IFN-γ on basal or IL-17-
induced (50 ng/ml) CXCL1 release over 24 h (n=8). *P<0.05 versus basal or IL-17 control 
values. (C) Effect of IFN-γ neutralization on its inhibitory activity towards IL-17-induced 
CXCL1 secretion. Cells were incubated with IL-17 (50 ng/ml) and IFN-γ (1.25 ng/ml) in the 
presence of IFN-γ-specific or control antibodies (at 10 μg/ml) for 24 h. *P<0.05 versus cells 
treated with IL-17 alone (n=6).(D) Effect of IL-17 and IFN-γ on CXCL1 mRNA expression. 
Cells were stimulated for 24 h with IL-17 (100 ng/ml) and IFN-γ at the doses indicated. 
*P<0.05 versus untreated cells (n=4). (E–G) Cells were transiently transfected with CXCL1 
promoter constructs and then stimulated with IL-17 (100 ng/ml) and/or IFN-γ (5 ng/ml) 
for 6 h as indicated. Luciferase activity was expressed as relative light units (RLU). (E) 
Activity of 1700 bp-length CXCL1 promoter after stimulation with IL-17 and/or IFN-γ. 
*P<0.05 versus unstimulated controls (n=4). (F) Effect of progressive 5’-deletions of the 
CXCL1 promoter on its responsiveness to IL-17. *P<0.05 versus unstimulated controls 
(n=4). (G) Effect of site-directed mutagenesis in the STAT1-binding site of the CXCL1 
promoter on its activity after stimulation with IL-17. #P<0.05 versus relevant control, n=5. 
(H) SP1 mRNA expression after stimulation with IL-17 and/or IFN-γ for 3 h. *P<0.05 
versus unstimulated controls (n=4).  
Figure 3. Identification of SP1 as a transcriptional mediator of CXCL1 promoter 
induction by IL-17. (A–C) Nuclear fractions from cells stimulated with IL-17 (100 ng/ml) 
and/or IFN-γ (5 ng/ml) were analysed using EMSA and a consensus oligonucleotide probe 
for SP1. (A) nuclear extracts were obtained from cells stimulated with IL-17 for various 
times. (B) nuclear extracts were isolated 6 h after stimulation with IL-17 and subjected to 
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EMSA in the presence of increasing concentrations of SP1-specific antibody (resulting in a 
supershift). (C) EMSA was performed with nuclear extracts from cells stimulated with IL-
17±IFN-γ for 6 h. (D–E) After stimulation with IL-17 (100 ng/ml) and/or IFN-γ (5 ng/ml) 
for 6 h, chromatin was isolated and precipitated using a SP1 antibody, and the DNA bound 
was identified by PCR. (F) Cells were transiently transfected with 10 nM of either SP1-
specific siRNA or scrambled siRNA, stimulated with IL-17 (100 ng/ml) for 24 h, and then 
assessed for CXCL1 mRNA expression. P<0.05 versus cells stimulated with IL-17 (*) in the 
absence of siRNAs or (#) in the presence of scrambled siRNA (n=4). 
Figure 4. Effect of STAT1 on IFN-γ-modulated CXCL1 induction. (A–D) Cells were 
transiently transfected with 10nM of either STAT1-specific siRNA or scrambled siRNA 
control, stimulated with IL-17 (100 ng/ml) and/or IFN-γ (5 ng/ml ) for 24 h, and then 
assessed by western blotting for (A–B) STAT3 protein expression and by RT-qPCR for (C) 
SP1, and (D) CXCL1 mRNA expression. P<0.05 versus cells stimulated with IL-17+IFN-γ (*) 
in the absence of siRNAs or (#) in the presence of scrambled siRNA (n=6). (E) Dose effect of 
IFN-γ on STAT1 binding to CXCL1 promoter, as assessed by ChIP.  In (A) a representative 
immunoblot is shown; In (B) immunoblot data quantified from six independent 
experiments.  
Figure 5. Contribution of SP1 and STAT1 to CXCL1 induction in HPMCs during 
peritonitis. (A–B) Cells were treated for 24 h with increasing doses of exemplary PD 
effluent drained during peritonitis and analysed for mRNA expression of (A) CXCL1, and 
(B) SP1. *P<0.05 versus untreated controls (n=4); (C): Cells were transiently transfected 
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with 10 nM SP1-specific siRNA or scrambled (scramb.) siRNA and then exposed for 24 h to 
peritoneal effluent (25% v/v) from a patient with peritonitis and assessed for CXCL1 
mRNA expression. P<0.05 versus cells treated with the dialysate (*) in the absence of 
siRNAs or (#) in the presence of scrambled siRNA (n=4); (D–H): Cells were exposed to 
peritonitis PD effluent (25% v/v) for 24 h in the presence or absence of (D–E) antibodies 
specific for TNFα (10 μg/ml) and IL-17 (0.5 μg/ml) or (G–H) IFN-γ (5-5000 pg/ml). Cells 
were then assessed for mRNA expression of (D, F) CXCL1, (E, G) SP1 or (H) STAT1. *P<0.05 
versus cells treated with the dialysate in the absence of (D-E) antibodies or (G-H) IFN-γ 
(n=4).  
Figure 6. (A-B): Effect of HPMC exposure to IL-17 and IFN-γ on neutrophil migration. 
(A) Effect of conditioned media from HPMCs on neutrophil migration. HPMCs were 
stimulated with IL-17 (100 ng/ml), IFN-γ (5 ng/ml) or IL-17±IFN-γ (n=3). The 
conditioned-media were collected after 24 h, diluted 1:1 (v/v) in plain medium and 
applied to the lower chambers of the Transwell systems; fMLP (10 nM) was used as a 
positive control; *P<0.05 versus medium from unstimulated cells. (B): Neutrophil 
migration through HPMC monolayers. HPMCs were established on the underside of 
Transwells and stimulated as above for 24 h (n=4). For both A and B, neutrophils (1.5 x 
106) were loaded into the upper Transwell chamber and cells that had migrated to the 
lower chamber were quantified using a standard curve prepared by determining 
myeloperoxidase activity in the lysates of known numbers of neutrophils. *P<0.05 versus 
untreated cells, #P<0.05 versus IL-17-stumulated cells (n=4). (C) CXCL1 binding to HPMCs 
in vitro. HPMCs were exposed to serial dilutions of recombinant CXCL1 for 30 min and 
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CXCL1 binding was detected by immunoassays. *P<0.05 versus untreated cells (n=5). (D) 
Implications of the present study. Neutrophil counts in the dialysate fluid from PD patients 
with acute peritonitis associate with IL-17 levels depending on the concentration of IFN-γ. 
They do not, however, correlate with the levels of CXCL1, a key mesothelial cell-derived IL-
17-induced neutrophil-chemoattractant. Thus, we sought to determine how IL-17 and IFN-
γ interact to modulate CXCL1 production by HPMCs. IL-17 initiates rapid transcription and 
translation of SP1, a transcription factor essential for the production of CXCL1. This 
process is amplified by TNFα but inhibited by IFN-γ operating through STAT1 pathway. 
Following the stimulation of HPMCs by IL-17 and IFN-γ, the CXCL1 is released and cell-
bound, which modulates accordingly transmesothelial migration of neutrophils. The 
effluent collected during peritonitis contains IL-17 and TNFα and is capable of stimulating 
HPMCs to produce CXCL1 through SP1 activation. Supplementing the effluent with IFN-γ, 
adding antibodies against IL-17 and TNF-α or the introduction of siRNA targeting SP1 
mRNA can suppress SP1 and inhibit CXCL1 induction. 
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